Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Euro long way from the governor’s mansion . . .
November 14, 2011
By: Gil Roth
President, Pharma & Biopharma Outsourcing Association
In this space in the September 2008 issue, I wrote about notions of risk in the financial sector and highlighted a book called When Genius Failed, by Roger Lowenstein. The book covered the collapse of Long-Term Capital Management (LTCM), a hedge fund that over-leveraged on its arbitrage deals and blew up when Russia defaulted on its debt in 1998. The collapse required a bailout from all the major investment banks of the era, including Goldman Sachs. The chief executive officer of Goldman at the time was Jon Corzine, who was later elected to the U.S. Senate and then became governor of my home state of New Jersey. I try to make it a practice not to write about politics in this space anymore, because I think it’s largely degenerated into high school football team boosterism, but bear with me. I voted against Gov. Corzine in the 2009 election. I didn’t like the way the state’s finances were being treated, but I really didn’t like the notion of a former Goldman Sachs CEO gaining another term at the helm. The ugliness of our plutocracy really came to the fore after the subprime crisis revealed the house of cards of our financial structure and its intertwining with the levers of government; I guess you could call my vote a pre-Occupy Wall Street moment. I’m increasingly glad I didn’t vote for the incumbent in 2009. Sure, Chris Christie, Gov. Corzine’s successor, has made his share of gaffes and has had to make some unpopular decisions on the state’s budget. Also, it’s apparently mandatory to criticize him for his weight, as though it’s a moral failing that precludes his ability to govern, but that’s a topic for another column. After Mr. Corzine lost his re-election bid, he went back to Wall St., taking over a brokerage named MF Global Holdings in early 2010. By Halloween 2011, MF Global declared bankruptcy, having over-extended itself to buy up Euro-debt, as per Mr. Corzine’s get-big-quick strategy. Like LTCM, MF Global was leveraged around 30 to 1, and when creditors got nervous over its bets, it was unable to get funding to pay loans. One potential investor/savior ran away screaming when its audit uncovered hundred of millions of dollars in missing funds the client side of MF’s brokerage. Mr. Corzine resigned after the bankruptcy and has allegedly hired a criminal defense lawyer. He was kind enough not to ask for his $12 million bonus on the way out the door, and has offered to help find clients’ missing money. People continue to crack jokes about Gov. Christie’s weight. Mr. Lowenstein, author of that book on LTCM, wrote a great piece at BusinessWeek about Mr. Corzine’s amazing fall. In it, he marvels over the ex-governor’s inability to learn the lessons of LTCM (given Mr. Corzine’s ringside seat for that meltdown), repeats the adage that the market can stay irrational longer than you can stay solvent, and rails against the continuing stupidity of financial types who consider liquid assets an escape hatch from risk. Ah, back to risk. My point here, as ever, is that we continue to fail to understand risk. In the R&D Outsourcing interviews I conducted for this issue, the issue of risk is the through-line, whether it be in terms of getting less risky compounds into the clinic or reducing the costs that go into development and lowering the price of failure. I don’t know how we make progress from here, but I think Mr. Corzine has helped demonstrate that we probably don’t need to have the finance guys make the big decisions. I’m just glad he’s not making decisions about my money anymore.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !